Federally-mandated quality control (QC) in Papanicolaou (Pap) smear testing requires rescreening of 10% of negative smears, to include cases selected randomly as well as smears from patients that may have a higher risk for developing cervical cancer based on clinical information. FDA approval of Neo
Endometrial cells and the AutoPap system for primary screening of cervicovaginal Pap smears
β Scribed by Ann E. Walts; Premi Thomas
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 89 KB
- Volume
- 27
- Category
- Article
- ISSN
- 8755-1039
- DOI
- 10.1002/dc.10175
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
In 1998, the AutoPap 300 received FDA approval for primary screening of conventional cervical smears. As approved, smears categorized as βno further reviewβ and comprising up to 25% of the smears screened by the AutoPap 300 can be reported as negative for malignant and dysplastic cells without screening by a cytotechnologist. We studied 106 conventional cervical smears in which glandular endometrial cells had been identified by manual screening to assess the ability of the AutoPap System (TriPath Imaging, Inc., Burlington, NC) to (1) designate conventional Papanicolaou smears that contain endometrial cells for βreview,β and (2) stratify smears that contain endometrial cells as more or less likely to be abnormal.
Although the number of cases in our study was small, our findings indicate that (1) the AutoPap System is slightly less sensitive than manual screening by experienced cytotechnologists for the detection of endometrial cells in conventional smears, as the System designated for βreviewβ 94.3% of all smears containing endometrial cells, 92.9% of smears reported as atypical glandular cells of undetermined significance (AGUS) or endometrial adenocarcinoma, and 100% of the four smears with subsequently confirmed endometrial adenocarcinomas, (2) ranking of smears into quintiles by the AutoPap System did not provide additional diagnostically useful information with respect to endometrial pathology, (3) the number of endometrial cells in the smears did not correlate with quintile assignment, and (4) for most patients, routine use of the AutoPap System for primary screening of conventional cervical smears is unlikely to contribute to delay in the diagnosis of clinically significant endometrial lesions. Diagn. Cytopathol. Diagn. Cytopathol. 2002;27:232β237. Β© 2002 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Background: The autopap 300 qc system (tripath imaging, inc., burlington, nc) is an automated device that was designed to screen conventionally prepared cervical smears and, more recently, thin-layer slide preparations. the system has been tested in large clinical trials. ## Methods: A total o
## Background: Autopap (currently focalpoint) is a computerized scanning system for the primary screening of cervicovaginal smears. for smears indicated to require further review, the system provides maps (papmaps) to identify the most abnormal areas of the smear. ## Methods: To study the effect
## Background: The autopap 300 qc system is an automated device for the analysis of conventionally prepared cervical cytology slides. the autopap system selects an enriched population of cases for human quality control (qc) review. the device assigns a score based on the likelihood that a slide is
## RESULTS. For the historic sensitivity study, the percentages of cases present within